Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status Prescription
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
NDC Product Code 72205-007; 69097-948; 59923-722; 59651-204; 0378-2511; 55111-893; 55111-496; 0054-0272; 72205-006; 70756-816; 50268-154; 51407-095; 15308-0714; 16714-467; 62756-239; 67877-458; 64980-277; 55512-0015; 16729-072; 68001-487; 67877-459; 55111-497; 51079-510; 35369-0010; 54893-0002; 70756-815; 63482-099; 60687-149; 0004-1101; 62331-043; 72485-205; 53183-4009; 69539-019; 0004-1100; 65162-843; 16729-073; 72969-094; 62756-238; 16714-468; 68554-0033; 69097-949; 54245-7014; 72485-204; 62756-088; 0054-0271; 59651-205; 0093-7473; 72606-555; 76302-001; 69539-020; 65162-844; 53104-7618; 0378-2512; 51407-096; 81955-0001; 63759-0001; 49452-1713; 68001-488; 65129-1241; 64980-276; 0093-7474; 72606-554; 59923-721
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.0010.007992%
Abdominal pain07.01.05.0020.029838%
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abortion spontaneous18.01.04.001--Not Available
Abscess11.01.08.0010.003463%Not Available
Acne23.02.01.001--Not Available
Actinic keratosis23.01.06.0010.002131%Not Available
Acute hepatic failure09.01.03.001--Not Available
Acute leukaemia16.01.02.001; Available
Acute myeloid leukaemia16.01.05.001; Available
Acute myocardial infarction02.02.02.001; Available
Acute prerenal failure24.06.02.003; Available
Acute promyelocytic leukaemia16.01.05.003; Available
Acute respiratory distress syndrome22.01.03.0010.000417%
Acute respiratory failure22.02.06.001; Available
Ageusia17.02.07.001; Available
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase abnormal13.03.01.0010.000533%Not Available
Alanine aminotransferase increased13.03.01.003--
Altered state of consciousness19.07.01.003; Available
Amylase increased13.05.01.0090.001332%
Anaphylactic reaction24.06.03.006;
The 1th Page    1 2 3 4 5    Next   Last    Total 35 Pages